Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript November 6, 2024Arbutus Biopharma Corporation reports earnings inline with expectations.
Arbutus Biopharma Corp (ABUS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | LMR Partners Ben Levine, Andrew Manuel And Stefan Renold | 197,025 | $758,546 | -23% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.95 | 1,000 | Director | 1,000 | 2015-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.69 | 8,846 | Director | 46,069 | 2024-08-14 | Filing | |
| $2.31 | 4,358 | Officer | 125,542 | 2024-02-02 | Filing | |
| $2.31 | 9,593 | Officer | 181,907 | 2024-02-02 | Filing | |
| $2.31 | 9,982 | Officer | 1,485,121 | 2024-02-02 | Filing | |
| $2.31 | 10,164 | Officer, Director | 1,504,793 | 2024-02-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,390,300 | $25,975,752 | 0% | |
| 2. | 6,984,112 | $17,460,282 | 0% | |
| 3. | 5,988,883 | $14,972,208 | 0% | |
| 4. | 2,817,695 | $7,044,982 | 0% | |
| 5. | 2,396,760 | $5,991,900 | 0% |
News See All
10 Best Debt-Free Penny Stocks to Buy Now
Inflation in the U.S. has dropped to the lowest level since 2021, setting the stage for the Federal Reserve to cut interest rates.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Second Quarter Financial Results and Corporate Update. [Operator Instructions].
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript
Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update Conference Call.
12 Best Micro Cap Stocks To Invest In
In this piece, we will take a look at the 12 best micro cap stocks to invest in.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Q2 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2023 First Quarter Financial Results and Corporate Update Conference Call.
5 Best Debt Free Penny Stocks to Invest In
In this article, we will be taking a look at the 5 best debt free penny stocks to invest in.
Billionaire Hedge Funds
